The adjustment in price target by Canaccord Genuity reflects a minor change in valuation assumptions or expectations for Arcturus Therapeutics. While the reduction is minimal, it suggests a slight recalibration of future prospects. However, maintaining a Buy rating indicates a continued positive outlook on the company's performance. This could lead to a neutral short-term impact on the stock as the market digests the slight adjustment in expectations against the backdrop of an overall positive recommendation.